Navigation Links
ChanTest Announces Third User Meeting: Partnerships in Drug Discovery
Date:8/6/2013

Cleveland, OH (PRWEB) August 06, 2013

Partnerships between industry and vendors have a positive impact on the drug discovery industry when the right companies come together, as they allow for innovation and optimize the process of identifying the right drugs faster and more effectively. On Friday, September 27, 2013, ChanTest will host a third User Meeting: "Partnerships in Drug Discovery" to be held at the Westin Boston Waterfront Hotel, 425 Summer Street, Boston, MA.

The keynote speaker of this complimentary event will be Christopher Penland, Ph.D., Senior Director of Research at the Cystic Fibrosis Foundation, who will speak about the Foundation’s efforts to work with the scientific community to find new solutions for cystic fibrosis.Other presentations will highlight ion channels for pain drug discovery and neuropathology, the development of gut-targeted therapeutics, and strategies for merging automated patch clamp techniques with high-throughput screening.

"We are again looking forward to bringing together a range of experts from safety and discovery labs to highlight their work and the value of their collaborations with ChanTest," explained Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest.

The event is co-sponsored by Acea Biosciences, Axion Biosystems, AxioGenesis, Battelle, Cellular Dynamics International, Molecular Devices, Renovo Neural, Sophion and Sygnature Discovery.

Register to attend.

Friday, September 27, 2013
3rd ChanTest User Meeting: Partnerships in Drug Discovery
Westin Boston Waterfront Hotel
425 Summer Street
Boston, MA 02210

FURTHER INFORMATION
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:
Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 300 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey over the past eight years. ChanTest is based in Cleveland, Ohio. Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10997636.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. ChanTest Announces ChansPorter™ Assays to Accelerate Drug Development for Cystic Fibrosis Patients
2. New Teeth Whitening Procedure Effective On Teeth of Elderly, and Darkly Stained by Tetracycline, San Antonio Cosmetic Dentist Edward Camacho Announces
3. Diet Doc Weight Loss Plans Announces New Fat Burning Foods That Allow Patients to Lose Weight Fast and Decrease Bone Marrow Fat
4. Migraine Research Foundation Announces Newly Expanded and Updated Headache Doctor Lists
5. Leading Shopping Cart Software Expert, Shopping Cart Elite, Officially Announces The Launch Of Ebridalsuperstore.com.
6. Help Desk Software Provider iSupport Software Announces Version 12.5
7. hCGTreatments / Diet Doc Prescription Weight Loss Plans Announces New Quick Weight Loss Supplement 7-Keto DHEA Designed To Accelerate Results Naturally
8. hCGTreatments / Diet Doc Weight Loss Diets Announces Medical Diet Plans Designed to Promote Fast Weight Loss While Lowering Cholesterol Levels
9. Internet Marketing Firm Web-Op Announces Launch of KingSupplements.com
10. Clay Park Tower Apartments, One of San Francisco’s Top Pacific Heights Apartment Complexes, Announces 100% Occupancy
11. Spectrum Surgical Announces Dual-Chuck® Orthopedic Pin Insertion Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... Raton (PRWEB) , ... September 19, 2017 , ... ... the El Naturalista brand, developed by ACPG Laboratories, is coming soon to RonnieColemanNutrition.com. ... in Spain, and El Naturalista is a trusted, well-respected brand reliant on the ...
(Date:9/19/2017)... ... ... For decades doctors, nurses, and other healthcare providers have been trained to ... calculating their cardiovascular disease (CVD) risk in the next 10 years. , Imagine ... an estimated 10-year risk prediction! , Imagine if the weatherman says there is a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... with the Davidson Fellows Scholarship on September 27 at a reception in Washington ... Technology, Engineering, Mathematics, Literature and Music. , “I am honored to be a ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency nursing expertise, skill ... Emergency Nurse (CEN®) certification according to a large-scale study announced today by ... conducted by the Human Resources Research Organization (HumRRO) in late 2016 and early ...
(Date:9/18/2017)... Bangkok, Thailand (PRWEB) , ... September 19, 2017 ... ... in Asia Pacific’s protein ingredient market , expected to grow at the ... Frost & Sullivan sharing the ‘Global Food Protein Trends & Growth Opportunities in ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
Breaking Medicine Technology: